tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Cancer'

PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology

PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology

Written by Ι Stock Market Media — June 6, 2018

PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA).  It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, ...

Read More →
0

PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer

PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer

Written by Ι Stock Market Media — May 21, 2018

PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application (IND) to the U.S. FDA.  It’s an IND that has been eagerly anticipated by the company’s shareholders since PharmaCyte met with the FDA in early 2017, and it would lay out PharmaCyte’s planned Phase 2b clinical trial for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer or LAPC.

The key ...

Read More →
0

Plandai Biotechnology Gains Credibility with NutriBullet Deal

Plandai Biotechnology Gains Credibility with NutriBullet Deal

Written by Ι Stock Market Media — April 26, 2017

Plandaí Biotechnology (OTCQB: PLPL) expects Capital Brands, LLC, the developer, marketer, and distributor of both the wildly popular NutriBullet and NutriBullet SuperFoods, to launch its reformulated product, SuperFood Fat Burning Boost®, next month. SuperFood Fat Burning Boost® is being reformulated to include Plandaí’s Phytofare® Catechin Complex. This is a landmark moment for a company like Plandaí Biotechnology that has just recently moved from solely a research and development company to focusing more on sales and ...

Read More →
0

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

Written by Ι Stock Market Media — December 12, 2016

All of the pieces are starting to fall into place for PharmaCyte Biotech (OTCQB: PMCB) and its upcoming human clinical trial in advanced pancreatic cancer. Just one week after the U.S. Food and Drug Administration (FDA) granted the biotech a pre-IND (Investigational New Drug) meeting to discuss the company’s clinical trial, PharmaCyte qualified to use its multi-million dollar “at-the-market” funding arrangement with Chardan Capital in order to enroll every single patient into its ...

Read More →
0

As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection

As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection

Written by Ι Stock Market Media — July 19, 2016

Worldwide the number of people living with diabetes has reached 422 million, and if the current trend continues, over 700 million people are expected to be living with diabetes by 2025. Diabetes has clearly become a healthcare crisis on a global scale, and PharmaCyte Biotech (OTCQB: PMCB) recently received some good news in the form of patent protection that will help the company do its part in bringing a treatment to tens of ...

Read More →
0

PharmaCyte Biotech’s Cancer Treatment Shows “Complete Tumor Remission” in Published Preclinical Study

PharmaCyte Biotech’s Cancer Treatment Shows “Complete Tumor Remission” in Published Preclinical Study

Written by Ι Stock Market Media — June 3, 2015

NEW YORK, NY — PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate video by the company. In that video, PharmaCyte revealed that its cancer treatment of Cell-in-a-Box® plus low doses of the anticancer drug ifosfamide was able to produce “complete tumor remission in all animals” that received the treatment on days 2-6 of a previously published preclinical study.

It was a study ...

Read More →
0
Page 1 of 11 12345...»
ContactUs.com